| Name | Title | Contact Details |
|---|
Lynxcom Partners is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens.